NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Liquidia Corporation (LQDA) Stock Analysis

Liquidia Corporation (LQDA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

LQDA

$68.66

+$0.03 (+0.04%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LQDA with… →

LQDA Key Statistics

As of Sep 4, 2026
Trading
Open
$67.91
Previous Close
$68.63
Day's Range
67.40–69.47
52-Week Range
21.15–93.61
Volume
900.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
$6.15B
P/E Ratio
49.04
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
12.15
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.63
EPS (ttm)Profit attributable to each share over the last twelve months.
1.40
Financials (FY)
Revenue (FY)
$158.32M+1031.18%
Net Income (FY)
−$68.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
30.74%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
89.51M
1-Year Return
+138.07%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.83M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LQDA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+99.07%
2025+193.28%
2024−2.24%
2023+88.85%
2022+30.80%
2021+65.08%
2020−31.07%
2019−80.24%
2018 (partial year)+95.14%

As of September 4, 2026.

LQDA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$158.32M−$68.92M−43.5%
2024$14.00M−$128.29M−916.6%
2023$17.49M−$78.50M−448.9%
2022$15.94M−$41.02M−257.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$158.32M$145.08M−$51.38M−$68.92M−43.5%
2024$14.00M$8.12M−$121.29M−$128.29M−916.6%
2023$17.49M$14.60M−$73.38M−$78.50M−448.9%
2022$15.94M$13.08M−$38.77M−$41.02M−257.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LQDA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricLQDADrug Manufacturers - Specialty & Generic medianvs median
P/E49.0419.27155% above
P/S ratio13.632.305.9x the median
Profit margin30.74%−3.14%33.9 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Liquidia Corporation (LQDA) is capitalised at $6.15B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 216.

LQDA last closed at $68.66 on September 4, 2026. That is +$0.03 (+0.04%) against the previous close. Over the past 52 weeks the price has ranged from $21.15 to $93.61. The latest close sits 224.63% above that 52-week low.

Financial Health

In fiscal 2025, Liquidia Corporation reported revenue of $158.32M. Against the prior fiscal year total of $14.00M, that is a change of +1,031.18%. The same year closed with a net loss of $68.92M. Profit margin runs at 30.74%. That is 33.9 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 1.4.

Across the 4 fiscal years on file, revenue moves from $15.94M in 2022 to $158.32M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 49.04. That is 154.55% above the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 12.15. The price-to-sales ratio is 13.63. On price-to-sales that is 5.9 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.54. Daily returns over the trailing 8 years annualize to a volatility of 85.22%. Over the trailing twelve months the price has returned +138.07%. Measured over 5 years, that is +90.45% a year compounded.

Growth & Income

The record shows no dividend for LQDA.

Across the complete calendar years on file, 2025 returned +193.28% and 2019 returned −80.24%. Of the 7 complete calendar years on file, 4 finished higher. So far in 2026 the price is +99.07%.

Peer Comparison

Liquidia Corporation (LQDA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Liquidia Corporation LQDA $6.15B 49.0
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Liquidia Corporation trades at a P/E of 49.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Visit website →